KR20060010779A - Nipple device - Google Patents

Abstract

A nipple device (10), comprising a nipple (11) and a nipple holding body (15) holding the nipple (11), wherein a liquid permeable body (25) is installed in the nipple holding body (15), and a cap (17) is installed on the nipple holding body (15). A medicine container (20) covered by a film (21) is stored in the cap (17). When the cap (17) is installed on the nipple holding body (15), the projection (19) of the nipple holding body (15) pierces the film (21).

Description

Nipple Device {NIPPLE DEVICE}

The present invention relates to a nipple device capable of administering a medicament to an infant.

Conventionally, a pacifier filled with a medicament is known as the administration of a medicament while being sucked to an infant (see, for example, Japanese Patent Laid-Open No. 2001-511644).

Such a Pacifice has a mouthpiece, and the tablet is placed in an empty space of the mouthpiece. When the infant wears such a mouthpiece, the tablet is administered to the infant.

In the above-described conventional passifier, the tablet is placed in the empty space of the mouthpiece. However, when the tablet is replenished with the tablet, the tablet must be placed in the empty space of the mouthpiece, and the replenishment work is complicated.

Moreover, although it is necessary to wash | clean a passivator regularly, since a perciphere is comprised integrally, a container washing operation cannot be performed.

Disclosure of the Invention

The present invention has been made in consideration of such a point, and an object of the present invention is to provide a nipple device that can easily refill and clean a medicine.

The present invention includes a nipple, a nipple support for supporting a nipple, and a cap fitted to the nipple support, wherein a drug container is filled in the cap and the nipple side is covered with a film, and the nipple support has a cap. It is a nipple apparatus provided with the breaking part which breaks a film when it fits into this nipple support body.

The present invention provides a nipple support on a nipple support, wherein the liquid permeable body extends into the nipple, and the break portion of the nipple support consists of a projection sticking through the film.

The nipple apparatus is provided with a male screw on the nipple support, and a female screw fitted to the male screw in the cap.

This invention is a nipple apparatus which consists of a plate-shaped body which a liquid permeable body contacts the film of a chemical | medical agent container part, and the rod-shaped body extended from this plate-shaped object to the nipple side.

An opening is provided in the plate-shaped body of a liquid permeable body, and a processus | protrusion is a nipple apparatus which protrudes from a nipple side to this chemical | medical agent container side via this opening.

The present invention is a nipple device characterized in that the drug container portion is made of a drug container provided in the cap.

The present invention is a nipple device, characterized in that the drug container portion is composed of a region partitioned by a film in the cap.

The nipple apparatus has a communication space in which the nipple support body communicates with the nipple, and the communication space is provided on the side of the medicine container and is covered by a partition wall having a communication port.

The nipple device is characterized in that the break portion of the nipple support consists of an end portion of the partition wall.

The nipple device according to the present invention is provided with a one-way valve for introducing a drug into the nipple support from the drug container portion in an opening of the partition wall.

The present invention includes a nipple support having a nipple, a container housing that supports the nipple and communicates with the nipple side, and a cap that is freely mounted on the nipple support to cover the container housing, wherein the medicine is contained in the container housing. A nipple device, which is filled, and has a medicine container having an opening on the nipple side.

The present invention provides a nipple device, wherein a container guide portion is provided with a cylindrical guide projecting toward the nipple side, and the chemical | medical agent container has a spout opening inserted into this cylindrical guide.

The present invention provides a nipple device in which a medicine container is free to be detached from a container storage portion, and a fitting rib is fitted to the cylindrical guide of the container storage portion in a cap.

The present invention provides a nipple device comprising a pressurizing portion that is made of a flexible material and is fixed in a container storage portion and presses and crushes the chemical container in a cap.

The present invention is a nipple device wherein the medicament contains a xylitol component. The present invention is a nipple device characterized in that the drug contains a virus trapping composition. The present invention is a nipple device characterized in that the virus trapping composition contains water extract of bird's nest and / or enzyme treatment of bird's nest as an active ingredient.

1 is a side cross-sectional view showing a first embodiment of a nipple device according to the present invention.

2 is an exploded view of the nipple device.

3 is a view from the direction of arrow III in FIG. 1;

4 is a side cross-sectional view showing a second embodiment of the nipple device according to the present invention.

5 is an exploded view of the nipple device.

6 is a perspective view showing a third embodiment of the nipple device according to the present invention;

7 is a partial cross-sectional view of the nipple device.

8 is a view showing a modification of the nipple device according to the present invention.

9 is a view showing a modification of the nipple device according to the present invention.

10 is a chart showing the results of investigating the influenza virus infection neutralization activity of the virus trapping composition.

11 is a table showing the results of examining the molecular species and content of sialic acid contained in the virus trapping composition.

Fig. 12 shows the results of investigating the glycopeptide contained in the virus trapping composition by SDS-PAGE to examine its binding to influenza virus.

To practice the invention  for Best  shape

EMBODIMENT OF THE INVENTION Hereinafter, embodiment of this invention is described with reference to drawings.

1 to 3 are views showing a first embodiment of the nipple device according to the present invention. 3 is a view seen from the direction of arrow III in FIG. 1.

As shown in FIGS. 1 to 3, the nipple device 10 includes a nipple 11 that an infant bites in the mouth, a nipple support 15 for supporting the nipple 11, and a nipple 11 from the nipple support 15. The liquid permeable body 25 extended into the inside) and the cap 17 fitted to the nipple support body 15 are provided.

Moreover, the chemical | medical agent container (pharmaceutical container part) 20 filled with the liquid chemical | medical agent, for example, the liquid chemical which contained the xylitol component of caries prevention, is provided in the cap 17, and this chemical | medical agent container 20 is provided. The nipple 11 side of the nipple is covered with a film 21 made of silver paper or resin. In addition, when the cap 17 is fitted to the nipple support 15, the nipple support 15 is provided with a projection 19 to pierce the film 21 of the medicine container 20. This projection 19 functions as a fracture portion that breaks the film 21 when the cap 17 is fitted to the nipple support 15.

Next, the structural member of each part is demonstrated in detail. First, the nipple 11 has a cylindrical nipple body 11a and a plate-shaped base end 11b provided at the base end of the nipple main body 11a. The nipple main body 11a is provided with the opening 12 which supplies the chemical | medical agent sent through the liquid permeable body 25 to the outside.

Moreover, the nipple support 15 has the cylindrical part 15a and the large diameter part 15b of diameter larger than this cylindrical part 15a. The proximal end 11b of the nipple 11 is inserted into the large diameter portion 15b of the nipple support 15, and the support frame 13 is inserted into the large diameter portion 15b from the outside of the proximal end 11b. Is embedded. In this way, the nipple 11 is supported by the nipple support 15.

Moreover, the chemical | medical agent container 20 is settled in the cylindrical part 15a of the nipple support body 15, and this chemical | medical agent container 20 is joined to the cap 17. As shown in FIG.

The nipple 11 side of the chemical | medical agent container 20 is covered with the film 21 as mentioned above, and this film 21 is easily stuck by the protrusion 19 of the nipple support body 15, and is damaged.

Moreover, the fluid permeable body 25 has the same shape as the film 21 of the chemical | medical agent container 20, and the disk-shaped plate-shaped body 25b and the plate-shaped body 25b which contact this film 21 It has the rod-shaped body 25a extended to the nipple 11 side from the side. The liquid permeable body 25 is made of a sponge material as a whole, and allows the medicine in the medicine container 20 to pass to the nipple 11 side.

Moreover, the opening 26 located under the rod-shaped body 25a is formed in the plate-shaped body 25b of the liquid permeable body 25. As shown in FIG. By inserting the projection 19 of the nipple support 15 into the opening 26 of the plate-shaped body 25b, the liquid permeable body 25 can be fixed by the nipple support 15.

The rod-like body 25a of the liquid permeable body 25 preferably has the same outer surface shape as the inner surface shape of the nipple body 11a of the nipple 11, in which case the liquid permeable body 25 is the nipple body. Positioning can be fixed by 11a.

Moreover, the projection 19 of the nipple support body 15 is supported between the cylindrical part 15a and the large diameter part 15b, and the tip of the side of the film 21 of the chemical | medical agent container 20 is sharp.

In addition, a male screw 16 is provided on the outer surface of the cylindrical portion 15a of the nipple support 15, and a female screw 18 fitted to the male screw 16 is provided on the inner surface of the cap 17. However, the cylindrical portion 15a and the cap 17 may be fitted by fitting one touch instead of screwing.

In any case, the cylindrical portion 15a of the nipple support 15 and the cap 17 are fitted in a sealing shape.

Next, the effect | action of this embodiment which consists of such a structure is demonstrated.

First, as shown in FIG. 2, the projection 19 of the nipple support 15 is inserted into the opening 26 of the plate-shaped body 25b of the liquid permeable body 25.

Next, the base end portion 11b of the nipple 11 is inserted into the large diameter portion 15b of the nipple support 15, and the support frame 13 is inserted into the large diameter portion 15b to nipple 11. It is supported by the support 15.

In this case, it is preferable to sandwich a sealing material between the large diameter part 15b of the nipple support body 15, and the support frame 13. As shown in FIG. Moreover, the projection 19 of the nipple support body 15 is inserted in the opening 26 of the liquid permeable body 25, and the rod-shaped body 25a of the liquid permeable body 25 is formed in the inner surface of the nipple main body 11a. By contacting, the liquid permeable body 25 is fixedly positioned by the nipple support 15 and the nipple 11.

Next, the female screw 18 of the cap 17 is fitted to the male screw 16 of the nipple support 15, and the cap 17 is fitted into the cylindrical portion 15a of the nipple support 15. In this case, when the chemical | medical agent container 20 is previously attached by the adhesive agent in the cap 17, and the cap 17 is inserted in the cylindrical part 15a of the nipple support body 15, the chemical | medical agent container 20 is carried out. Film 21 is stuck by the projection 19 of the nipple support 15 and broken.

When the film 21 is damaged, the liquid drug (containing the xylitol component) in the chemical container 20 moves to the nipple 11 side via the liquid permeable body 25.

When the infant bites the nipple 11, the drug transferred to the nipple 11 side by the liquid permeable body 25 enters into the infant's mouth from the opening 12 of the nipple main body 11a and then, by the xylitol component. Tooth decay can be prevented.

Moreover, when all the chemical | medical agent in the chemical | medical agent container 20 is consumed, the cap 17 and the chemical | medical agent container 20 are removed from the nipple support body 15, and the new cap which has the chemical | medical agent container 20 with which the chemical | medical agent was filled in advance ( 17) to the nipple support 15.

Moreover, after using the nipple apparatus 10 for a long time, each structural component can be disassembled and the each structural member can be wash | cleaned by the method of the reverse of the above (refer FIG. 2).

According to this embodiment as mentioned above, when the chemical | medical agent in the chemical | medical agent container 20 is consumed, only the new chemical | medical agent container 20 and the cap 17 are attached to the nipple support body 15, and it is easy and simple chemical | medical agent Can be supplemented. In addition, only by disassembling each structural member, washing of each structural member can be performed easily.

4 and 5, a second embodiment of the nipple device according to the present invention will be described. In addition, in 2nd Embodiment shown in FIG. 4 and FIG. 5, the same code | symbol is attached | subjected to the same part as 1st Embodiment shown in FIGS. 1-3, and detailed description is abbreviate | omitted.

As shown in FIG. 4 and FIG. 5, the nipple device 10 includes a nipple 11 that the infant bites on the mouth, a nipple support 15 for supporting the nipple 11, and a cap fitted to the nipple support 15. (17) is provided.

Moreover, the film 21 is provided in the cap 17. In the cap 17, a liquid drug, for example, a liquid drug containing a xylitol component for preventing tooth decay, is filled in a region 30 partitioned by the film 21. In this case, the area | region 30 divided by the film 21 in the cap 17 comprises a chemical | medical agent container part.

In addition, when the cap 17 is fitted to the nipple support 15, the end portion (breaking portion) 15d of the partition wall 15c of the nipple support 15, which will be described later, breaks the film 21.

By the way, the nipple support 15 has the cylindrical part 15a and the large diameter part 15b of the large diameter provided in the one side of this cylindrical part 15a, and the partition wall 15c mentioned above on the other side of the cylindrical part 15a is mentioned. ) Is provided.

The nipple support 15 which has such a structure has the communication space 33 which communicates in the nipple 11 in the inside, and this communication space 33 is covered by the partition wall 15c mentioned above. Moreover, the communication port 31 is provided in the partition wall 15c, and the one-way valve which seals the communication port 31 to the surface of the communication space 33 side of the partition wall 15c so that opening and closing is freely possible. (32) is attached. This one-way valve 32 flows the chemical | medical agent in the area | region 30 into the communication space 33, and the chemical | medical agent in the communication space 33 cannot move to the area | region 30 side.

Next, the effect | action of this embodiment which consists of such a structure is demonstrated.

First, as shown in FIG. 4, the base end part 11b of the nipple 11 is inserted in the large diameter part 15b of the nipple support body 15, and the support frame 13 is inserted in this large diameter part 15b, The nipple 11 is supported by the nipple support 15.

Next, the female screw 18 of the cap 17 is fitted to the male screw 16 of the nipple support 15, and the cap 17 is fitted into the cylindrical portion 15a of the nipple support 15. In this case, when the chemical | medical agent is filled in the area | region 30 partitioned by the film 21 in the cap 17 previously, and the cap 17 is inserted in the cylindrical part 15a of the nipple support body 15, The film 21 in the cap 17 is broken by the end 15d of the partition wall 15c of the nipple support 15.

When the film 21 breaks, the chemical in the region 30 flows into the communication space 33 of the nipple support 15 via the communication port 31 and the one-way valve 32, and then the communication space 33. The drug in) moves to the nipple 11 side.

When the infant bites the nipple 11, the drug which has moved to the nipple 11 side enters the infant's mouth from the opening 12 and can prevent tooth decay by the xylitol component.

In addition, when all the chemical | medical agent in the area | region 30 of the cap 17 is consumed, the cap 17 is removed from the nipple support 15, and the new cap 17 with which the chemical | medical agent was filled in advance to the nipple support 15 was carried out. Mount it.

Moreover, after using the nipple apparatus 10 for a long time, each component component is disassembled and the each component component is wash | cleaned by the method of the reverse of the above (refer FIG. 5).

According to the present invention as described above, when the medicine is consumed, the medicine replenishment can be easily and simply performed, and each constituent member can be disassembled to facilitate the cleaning.

6 to 9, a third embodiment of the nipple device according to the present invention will be described.

As shown in FIG. 6 and FIG. 7, the nipple device 10 has a nipple 11 that the infant bites on its mouth, and a container housing 43 that supports the nipple 11 and communicates with the nipple 11 side. A nipple support 15 and a cap 42 are attached to the nipple support 15 so as to swing freely and cover the container storage portion 43.

Among these, the nipple 11 has a hollow shape, and as described later, a fluid-like drug filled in the drug container 45, for example, a drug containing xylitol component for preventing tooth decay, is sent and stored. . In addition, the nipple 11 is provided with an opening 12 for supplying the medicine stored therein outward.

The nipple support 15 has a flange 40 supporting the nipple 11 and a flange cover 41 provided on the flange 40, and the container housing portion 43 is provided in the flange cover 41.

The container housing part 43 provided in the flange cover 41 is open | released at the top, and the chemical | medical agent container 45 filled with the liquid chemical | medical agent is accommodated in this container storage part 43. As shown in FIG. Moreover, the container accommodating part 43 is provided with the cylindrical guide 44 which protrudes toward the nipple 11 side, and the container accommodating part 43 is communicating with the nipple 11 side via this cylindrical guide 44. As shown in FIG.

By the way, the cap 42 is attached to the flange cover 41 of the nipple support 15 so as to be freely swinged through the swing shaft 42a, so as to cover the container housing portion 43 from above. Moreover, the fitting rib 48 which fits in the upper end part of the cylindrical guide 44 is provided in the inner surface of the cap 42. Thus, when the container housing portion 43 is covered by the cap 42, the fitting rib 48 is inserted into the container housing portion 43 and fitted to the upper end portion of the cylindrical guide 44.

In this case, the upper end of the cylindrical guide 44 has a tapered shape that is tapered toward the bottom, and the tip 48a of the fitting rib 48 ends downward corresponding to the upper end of the cylindrical guide 44. This taper has a tapered shape. In addition, the fitting rib 48 is preferably made of a flexible material.

Moreover, the liquid medicine is filled in the chemical | medical agent container 45, and it is accommodated in the container accommodating part 43 so that removal is free. That is, the chemical | medical agent container 45 consists of a flexible material as a whole, and the container main body 45a which accommodates a chemical | medical agent, and the spout 46 which consists of a hard material provided in the lower end of the container main body 45a is provided. Have As for the spout 46 of the chemical | medical agent container 45, the male screw 46a is formed in the outer surface, and the spout 46 is a cylindrical guide which guides the male screw 46a in the cylindrical guide 44 of the nipple support 15. It is inserted by screwing into the female screw (not shown) of (44).

In addition, the spout 46 may be inserted into the cylindrical guide 44 without forming a male screw on the outer surface of the spout 46.

In FIG. 6 and FIG. 7, in use, first, the cover 47 which is screwed into the spout 46 of the chemical | medical agent container 45 is removed, and the chemical | medical agent container 45 is the container of the nipple support 15. It is accommodated in the storage part 43. In this case, by screwing the male screw 46a of the spout 46 of the chemical | medical agent container 45 to the female screw of the cylindrical guide 45, the chemical | medical agent container 45 can be fixed firmly in the container accommodating part 43. FIG. Can be.

Next, the container main body 45a which consists of the flexible material of the chemical | medical agent container 45 is pressed from the upper side, and the chemical | medical agent in the container main body 45a is made to the nipple 11 side via the spout 46 and the cylindrical guide 44. Supply. Then, the chemical | medical agent container 45 is removed from the container storage part 43, the cap 42 is rocked through the oscillation shaft 42a, and the container storage part 43 is sealed by the cap 42. As shown in FIG. At this time, the fitting rib 48 provided on the inner surface of the cap 42 is fitted to the upper end of the cylindrical guide 44 to completely seal the upper end of the cylindrical guide 44.

Since the fitting rib 48 is formed by the flexible material as a whole, the upper end part of the cylindrical guide 44 can be reliably sealed with the front end 48a of the fitting rib 48.

When the infant bites the nipple 11, the medicine in the nipple 11 enters the infant's mouth from the opening 12 of the nipple 11, and can prevent tooth decay by the xylitol component.

Next, with reference to FIG. 8 and FIG. 9, the modified example of embodiment shown in FIG. 6 and FIG. 7 is demonstrated. In the embodiment shown in FIG. 8 and FIG. 9, the chemical container 45 is fixed to the container storage portion 43.

In FIG.8 and FIG.9, the same code | symbol is attached | subjected to the same part as embodiment shown in FIG.6 and FIG.7, and detailed description is abbreviate | omitted.

As shown in FIG. 8, the chemical | medical agent container 45 has the container main body 45a which consists of a Jabara flexible material filled with the chemical | medical agent, and the spout 46 provided in the lower end part of the container main body 45a.

Moreover, the nipple support body 15 which supports the nipple 11 has the flange 40 and the container accommodating part 43 provided in the flange 40. As shown in FIG.

The container accommodating part 43 is such that the chemical | medical agent container 45 is accommodated in the inside, and the cylindrical guide 44 which protrudes to the nipple 11 side is provided in the lower part of the container accommodating part 43. As shown in FIG.

Moreover, the upper part of the container storage part 43 opens, and the cap 42 which covers the storage part 43 is attached to the container storage part 43 so that swinging is possible freely. Moreover, the press part 49 which presses the jabara-shaped container main body 45a is provided in the inner surface of the cap 42.

In FIG. 8, the chemical | medical agent container 45 is accommodated in the container accommodating part 43 of the nipple support body 15, and the ejection outlet 46 of the chemical | medical agent container 45 is inserted in the cylindrical guide 44 at the same time.

At this time, a male screw is formed on the outer surface of the spout 46 of the chemical | medical agent container 45, and a female screw is formed in the inner surface of the cylindrical guide 44, and screwing the spout 46 into the cylindrical guide 44 is carried out. The chemical | medical agent container 45 can be firmly fixed to the container storage part 43. FIG.

Next, the cap 42 is rocked, and the container housing 43 is covered by the cap 42. In this case, the container main body 45a of the chemical | medical agent container 45 is pressed by the press part 49 of the cap 42, and the chemical | medical agent in the container main body 45a carries out the spout 46 and the cylindrical guide 44. FIG. It is sent to the nipple 11 side through.

Next, another modified example of the present invention will be described with reference to FIG. 9. In the modification shown in FIG. 9, the chemical | medical agent container 45 has the container main body 45a filled with the chemical | medical agent, and the spout 46 provided in the lower end part of the container main body 45a. In this case, the container main body 45a does not have a jabara shape, has a thin shape, and is made of a flexible material.

In FIG. 9, the chemical | medical agent container 45 is accommodated in the container storage part 43 of the nipple support body 15. In FIG. At this time, the male screw may be formed in the spout 46 of the chemical | medical agent container 45, the female screw may be formed in the cylindrical guide 44, and the spout 46 may be screwed in the cylindrical guide 44. FIG.

Next, the cap 42 is rocked, the container housing 43 is covered by the cap 42, and the container body 45 a of the chemical container 45 is pressed by the pressing unit 49. Thereby, the chemical | medical agent in the container main body 45 can be sent to the nipple 11 side via the spout 46 and the cylindrical guide 44. FIG.

10 to 12, a fourth embodiment of the nipple device according to the present invention will be described.

10 to 12 differ only in that a drug containing a virus trapping composition is used in place of a drug containing a xylitol component as a liquid drug, and other than that, the embodiment shown in FIGS. same.

That is, in the chemical | medical agent container 20 shown in FIGS. 1-3, the chemical | medical agent containing a virus trapping composition is filled instead of the chemical | medical agent containing a xylitol component, and the area | region 30 of the cap 17 shown in FIG. 4 and FIG. ), A drug containing a virus trapping composition is filled in place of the drug containing a xylitol component. In addition, in the chemical | medical agent container 45 shown in FIGS. 6-9, the chemical | medical agent containing a virus trapping composition is filled instead of the chemical | medical agent containing a xylitol component.

Next, this virus capture composition is explained in full detail. The virus trapping composition contains the water extract of the bird's nest and / or the enzyme treatment of the bird's nest as an active ingredient.

Among these, the bird's nest is a nest that Geumsayeon makes their saliva into a thread, and in China, it has been eaten as a high-quality food ingredient since ancient times, and it also makes lung disease, stomach cancer, expectoration, skin rejuvenation, and nourishment. It is also used as a food with a medical effect such as tonic. In addition, the component contains a lot of protein and sugar, and almost no fat.

Commercially available bird's nests include cavern nests and house nests, but both can be used. In addition, there are various types from the collected bird's nest to only dirt and hairs and stools removed from the bird's nest, and the bird's nest collected, bleached and washed repeatedly. It is preferable to use the bird's nest which is not performed.

The bird's nest extract of the present invention can be obtained, for example, as follows. 10 to 1,000 times the mass of ice is added to the bird's nest ground to a particle size of 2 mm or less, preferably 150 µm or less, and extracted after standing or stirring at 1 to 100 ° C for 0.5 to 48 hours. Filtration gives a filtrate. This filtrate can be used as it is or as a concentrated liquid to give the virus trapping composition of the present invention. In addition, these may be lyophilized or spray dried to be powdered.

In addition, the enzyme-treated product of the bird's nest was added to the bird's nest pulverized to the same size as above, and the extract (filtered before filtration) and the extract were extracted by adding the water or hot water of 10-1,000 times the mass thereof in the same manner as above. Filtrate or the solution which heat-processed the said extract liquid at 60-130 degreeC for 5 to 30 minutes can be obtained by enzymatic treatment.

As said enzyme, a protease is preferable, For example, what is marketed as an enzyme for foods generally can be used 1 type or in combination of 2 or more types. Specifically, `` pancreatin F '' (brand name, product made by Amano Seiyaku), `` Aroase AP-10 '' (brand name, Yakult Yakuhin Kogyo Co., Ltd.), `` pine soluble '' (brand name, Yakult Yakuhing High School), "Heat resistant protease thermoase" (trade name, Yamato Kasei Co., Ltd.) etc. can be illustrated.

The enzyme treatment conditions are not particularly limited, and the enzyme is adjusted to the optimum pH of the enzyme using the pH of the solution, and an appropriate amount of the enzyme is added thereto, followed by heat treatment for 0.5 to 24 hours at the optimum temperature of the enzyme, followed by heat treatment. It is good to deactivate. The filtrate obtained by filtering this reaction liquid can be used as it is, or it can concentrate suitably, and can be set as the concentrate, and can be used for the virus capture composition of this invention. In addition, these may be lyophilized or spray dried to be powdered.

500-200,000 are preferable and, as for the average molecular weight of the said enzyme treatment, 2,000-70,000 are more preferable.

The virus trapping composition of the present invention is a functional food material such as various sugars, lactic acid bacteria, bifidus bacteria, polyphenols, oligosaccharides, proteins, fatty acids, minerals, vitamins, It may contain components, such as plant fiber, sugar alcohol, surfactant, a preservative.

Although the form of the virus trapping agent of this invention does not have a restriction | limiting in particular, It is preferable to set it as a solution or a jelly agent. Moreover, since this virus capture composition is a component derived from food, it is highly safe and can also be used directly by a human body as an inhalant.

0.1-10,000 microgram / ml is preferable, and, as for content of the water extract of a bird's nest and / or the enzyme treatment product of a bird's nest in the virus capture composition of this invention, 0.2-400 microgram / ml is more preferable.

Each sample as shown in Table 1 was produced and used for the following tests.

Table 1

Sample grade Processing method Sialic Acid (Total) Protein content One Express Inactivation of heating (90 ° C.) after protease treatment (37 ° C., 16 hours). After filtration, freeze drying 7.6 mass% 64.4 mass% 2 First Class Inactivation of heating (90 ° C.) after protease treatment (37 ° C., 16 hours). After filtration, freeze drying 4.2 mass% 67.8 mass% 3 Class 2 Soak in water and boil, then decay after heating (90 ° C.) after protease treatment (37 ° C., 16 hours). After filtration, freeze drying 9.6 mass% 46.0 mass% 4 Express After grinding, sifted (150 μm mesh pass product), no protease treatment 5.0 mass% - 5 Express After grinding, sifted (150 µm mespass) and no protease treatment 9.5 mass% -

(1) infection neutralization test

By measuring the activity of lactate dehydrogenase (LDH) released from indigenous cells of Madin-Darby Canine Kidney (MDCK) cells infected with influenza virus, the degree of destruction of cell membranes by human influenza virus was measured (CT Guo, CH Wong, T Kajimoto, T Miura, Y Ida, LR Juneja, MJ Kim, H Masuda, TS uzuki, and Y Suzuki.Synthetic sialylphosphatidyl-ethanolamine derivatives bind to human influenza A viruses and inhibit viral infection.Glycoconjugate J., 1998, 15 (11) : 1099-1108).

That is, about 100 TC ID ₅₀ (50% Tissue-Culture Infectious Dose) of influenza virus (A / PR / 8/34 (H1N1) or A / Aichi / 2/68 (H3N2)), And EMEM medium (Eagles Minimum Essential Medium) containing each sample shown in Table 1 (final concentration 1 to 5000 µg / ml) were inoculated into MDCK cells monolayered in a 96-hole titer plate (flat bottom), and 34.5 It was incubated for 5 hours at ℃.

After incubation, the solution was removed and suspended in 100 µl of copper medium. After further incubation at 34.5 ° C for 20 hours, 12.5 μl of the obtained culture solution was diluted four-fold with 100 mM Tris hydrochloric acid buffer (pH 8.2), and 50 μl of reaction solution (2 mM NAD, 200 m-unit / ml of diaphorase ( diaphorase), 190 mM lithium lactate, 0.78 mM nitroblue tetrazolium, 100 mM Tris hydrochloric acid buffer (pH 8.2)). After 10 minutes incubation at 37 ° C., 100 μl of 0.5 M hydrochloric acid was added to stop the reaction. The absorbance at 550 nm (630 nm in contrast) was measured to determine LDH activity. Fetuin was also used as a positive control. Fetuin is a component contained in fetal bovine serum and is known to have influenza neutralizing activity. The result is shown in FIG.

As shown in FIGS. 10A and 10B, the IC ₅₀ for the human influenza virus (A / PR / 8/34 (H1N1) and A / Aichi / 2/68 (H3N2)) of Sample 1 was 80 It was found that it was μg / ml and had a strong inhibitory activity of 2 to 8 times that of the inhibitory activity of fetuin as a positive control. On the other hand, Sample 2 was found to have an inhibitory activity almost equivalent to fetuin against human influenza virus (A / PR / 8/34 (H1N1)).

In addition, for each sample described above, MDCK cells obtained by monolayer culture of EMEM medium containing a bird's nest solution (initial concentration of 5 mg / ml) diluted twice-fold using MDCK monolayer cells on a 96-hole titer plate (flat bottom) were used. After incubation at 37 ° C. for 25 hours, the lactic acid dehydrogenase (LDH) activity of the culture was measured to determine whether it was cytotoxic. All samples showed no cytotoxicity against MDCK cells and showed high safety. Could know.

(2) erythrocyte aggregation inhibition test

Dispense 25 µl of PBS into each well of a 96-hole titer plate (bottom U), add 25 µl of the test sample (samples 1 and 2) solution to the first row of the titer plate, and several times with a micropipette. Suction discharge was performed. 25 microliters of the wells of the first row were transferred to the second row, and suction suction was performed several times with a micropipette. This operation was performed similarly to the 3rd row and the 4th row, and the double dilution heat was produced.

After 25 microliters of the solution containing each virus shown in Table 2 was dispensed to each well, the titer plate was gently shaken and it was left to stand at 4 degreeC for 60 minutes. 50 μl of 0.5% (V / V) human erythrocyte suspension was dispensed into each well, the titer plate was gently shaken, and then allowed to stand at 4 ° C. for 60 minutes, followed by the settling of red blood cells to the bottom of each well. The presence or absence of aggregation was determined by the state, and the lowest concentration which could cause aggregation inhibition of each sample was computed. The results are shown in Table 2.

TABLE 2

As shown in Table 2, Sample 1 has a very low concentration of hemagglutination inhibitory activity against viruses except for A / Swine / Colorado / 1/77 (H3N2) among the influenza viruses (viruses isolated from humans, birds or pigs). It can be seen that. Meanwhile, it can be seen that Sample 2 exhibits hemagglutination inhibitory activity at low concentrations against viruses except for A / Memphis / 1/71 and A / Swine / Colorado / 1/77 (H3N2).

From the above result, it turned out that the samples 1 and 2 have the adsorption capacity with respect to a wide range of influenza virus.

(3) Molecular species and contents of sialic acid contained in samples 1 and 2

Influenza viruses have been found to recognize and bind to specific sugar chains containing sialic acid. Therefore, the molecular species and content of sialic acid in the bird's nest were examined by the following method (Hara, S., Yamaguchi, M., Takemori, Y., Nakamura, M., Ohkura, Y .: Highly sensitive determination of N-acetyl- and N-glycolylneuraminic acids in human serum and urine and rat serum by reverse d-phase liquid chromatography with fluorescence detection.J. Chromatogr., 377, 111-119 (1980), Hara, S., Takemori, Y , Yamaguchi, M., Nakamura, M., 0hkura, Y .: Fluorometric high-performance liquid chromatography of N-acetyl and N-glycolylneuraminic acids and its application to their microdetermination in human and animal sare.Analytical Biochem., 164, 138-145 (1987).

That is, each sample was heated in 20 μl of 2 M acetic acid at 80 ° C. for 3 hours to hydrolyze the glycosidic bond of sialic acid, and then 15.7 mg of fluorescent reagent (Sodium hydrosulfate, 2-mercaptoethanol ( 350 μl of 2-mercaptoethanol) and 7.9 mg of diamino-4,5-methylenedioxy benzene 2HCl (hereinafter referred to as 'DMB') made by Tooningakaku Co., Ltd. 20 microliters of what was added and was prepared in 5 ml, was added, and it heated at 50 degreeC and 2.5 hours in the dark.

In this reaction solution, 10 µl of the sialic acid fluorescent derivative was separated by HPLC using a COSMOSIL / COSMOGEL column (trade name, manufactured by Nakaray Tesque Co., Ltd.), and detected by a spectrophotometer (trade name "650-10S" manufactured by HITACHI). The result is shown in FIG.

As shown in FIG. 11, it turned out that both sample 1 and sample 2 contain sialic acid, and N-acetyl noiramic acid (NeuAc) is a main molecular species. In addition, although the ratio was small, it was found that N-glycolyl noiramic acid (NeuGc) was also contained. In addition, the N-acetyl noiramic acid content (12.25%) of Sample 1 was about 2 times higher than that of Sample 2 (6.52%), and the N-glycolyl noiramic acid content was 0.41% in Sample 1 and 0.09 in Sample 2. It was%.

From these results, it was suggested that sialic acid contained in Samples 1 and 2 closely resembles human sialic acid molecular species, and that proteins, peptides or lipid molecules containing these sialic acids are components that bind to influenza virus.

In addition, although sample 1 was recognized to have higher influenza virus binding activity and infection inhibitory activity than sample 2, the fact that sample 1 has a higher sialic acid content than sample 2 correlates well. It is suggested that acid containing molecules have antiinfluenza activity.

(4) The binding of influenza viruses to glycopeptides isolated by SDS-acrylamide gel electrophoresis (SDS-PAGE) was examined by the following method (Takashi Suzuki, Mikiko Tsukimoto, Masato Kobayashi, Akira Yamada, Yoshihiro Kawaoka). , Robert G. Webster, Yasuo Suzuki: Sialoglycoproteins that bind Influenza A Virus and Resist Viral Neuraminidase in Different Animal Sera.J. Gen. Virology, 75, 1769-1774 (1994).

That is, Sample 1 or Sample 2 (0.2 mg) dissolved in PBS was prepared in an equivalent amount of sample preparation buffer for SDS-PAGE (2% SDS, 10% glycerin, 0.0625 M Tris buffer containing 0.001% bromophenol blue, pH 6.8). Diluted with. Each sample was treated for 5 minutes in a boiling water bath, and non-reducing, SDS-polyacrylamide (SDS-PAGE plate: trade name "ET-1020L", atto) at a concentration of 10-20%. Manufactured by).

Glycopeptides developed on the gel were transferred onto a polyvinylidene difluoride (PVDF) membrane (made by Daiichi Chemical Co., Ltd.) and energized for 30 minutes at 2 mA / cm, and 5% bovine serum albumin (BSA)- Blocking was performed with PBS solution (0.2 mL / cm) at 4 ° C. for 15 hours. The PVDF membrane was washed five times with PBS, followed by addition of an influenza virus-0.25% BSA-PBS suspension prepared with 2HAU, and gently shaken at 4 ° C for 15 hours to avoid the effect of viral noiramidase. Thereafter, the virus suspension was removed, the PVDF membrane was washed five times with PBS, and then anti-influenza antibodies were added and shaken at 4 ° C for 2 hours. The antibody solution was removed, and this PVDF membrane was washed five times with PBS, and then 0.25% BSA- of ABC (peroxidase) kit (trade name, Vector Laboratories, Inc.) of VECTASTAIN kit. PBS solution was added and shaken at 4 ° C for 2 hours. The PVDF membrane was washed five times with PBS, and then, 10 ml of 0.1 M acetic acid (pH 6.0) was added to 200 ml of acetonitrile solution (110 mM 4-chloro-1-naphthol, 60 mM N, N-diethyl-p). The binding of the virus was examined using 200 µl of acetonitrile solution of N, N-diethyl-p-phenylenediamine-dihydrochloride and 1 µl of 31% hydrogen peroxide. The result is shown in FIG.

As shown in Fig. 12, both samples 1 and 2 are bands (in Fig. 4) that bind to influenza viruses (A / Aichi / 2/68 (H3N2) and A / Memphis / 1/71 (H3N2)). Bands). On the other hand, in the control experiment (Virus (-)) where all other manipulations were performed without adding a virus, the band bound to the virus could not be identified. It became. The degree of staining of the bands by Coomasibrillant Blue (CBB) (which can stain proteins and peptides) is almost the same in Samples 1 and 2, but the binding to the virus is stronger than Sample 2 in the sample. Also turned out to be many. From this result, it turned out that the sample 1 contains the glycopeptide containing sialic acid which binds to influenza virus more abundantly than the sample 2.

Since the virus trapping composition of the present invention contains a food-derived ingredient as an active ingredient, it has high safety and has adsorption capacity to various types of viruses, and thus can be used as a virus infection prevention agent or the like. In addition, by sending the virus trapping composition from the nipple 11 of the nipple device 10 into the infant's mouth, viral infection of the infant can be prevented.

Claims (17)

Nipples, A nipple support for supporting the nipple, With a cap fitted to the nipple support, In the cap, the medicine container part is filled with the medicine and the nipple side is covered with the film, The nipple support is provided with a break portion for breaking the film when the cap is fitted to the nipple support. The method of claim 1, A nipple support is provided with a liquid penetrating body extending into the nipple, The nipple device of the nipple support is made of a projection sticking through the film. The method of claim 1, A nipple device comprising a male screw provided in a nipple support, and a female screw fitted to the male screw in a cap. The method of claim 2, The liquid permeable body is comprised of a plate-shaped body which contacts the film of a chemical | medical agent container part, and the rod-shaped body extended from this plate-shaped body to the nipple side. The method of claim 4, wherein An opening is provided in the plate-shaped body of the liquid permeable body, and the protrusion is projected from the nipple side to the chemical | medical agent container side via this opening, The nipple apparatus characterized by the above-mentioned. The method of claim 1, A nipple device comprising a medicine container provided in the cap with a medicine container. The method of claim 1, A nipple device comprising a medicine container portion made up of an area defined by a film in the cap. The method of claim 1, The nipple support has a communication space in communication with the nipple, This communication space is provided on the chemical | medical agent container part side, and is covered with the partition wall which has a communication port. The method of claim 8, The nipple device of the nipple support comprises an end of the partition wall. The method of claim 8, A nipple device provided with a one-way valve for introducing a drug into the nipple support from the drug container portion in an opening of the partition wall. Nipples, A nipple support having a container housing portion that supports the nipple and communicates with the nipple side; A cap that is freely mounted on the nipple support to cover the container housing, A nipple device comprising a medicine container filled with a medicine in a container storage and having an opening on the nipple side. The method of claim 11, The cylinder storage part is provided with the cylindrical guide which protrudes to the nipple side, A nipple device characterized in that the medicine container has a spout inserted into the cylindrical guide. The method of claim 12, The chemical | medical agent container is free to remove from a container storage part, A nipple device provided with a fitting rib fitted to a cylindrical guide of a container storage portion in a cap. The method of claim 12, The drug container is made of a flexible material and is fixed in the container housing, A nipple device is provided with a pressing part for pressing and crushing a chemical container in a cap. The method of claim 1 or 11. A pacifier device comprising a xylitol component. The method of claim 1 or 11. The medicament contains the virus trapping composition. The method of claim 16, The virus trapping composition comprises a water extract of a bird's nest and / or an enzyme treatment of a bird's nest as an active ingredient.

Images